TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a ...

Key limitations included nonstandardized diagnostic criteria, proxy-derived activity/symptom measures, recall bias for ...

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers ...

Projectiles such as grass, dirt, and rocks caused 77% of injuries, and eye protection, including eyeglasses, was documented ...

For patients with a blood cancer, the choice of a chimeric antigen receptor (CAR) T-cell therapy or a bispecific antibody is rarely a simple one, explains Kerry Rogers, MD, associate professor at The ...